Tiziana Announces Availability of March 14 KOL Event Replay
Tiziana Life Sciences (Nasdaq: TLSA) announces the replay availability of its March 14 KOL event, "Foralumab Clinical Update in Multiple Sclerosis," along with presentation slides on its website. Zacks released a research note discussing positive clinical data for a SPMS patient treated for six months. Tiziana is focused on innovative immunotherapy approaches, including intranasal foralumab and milciclib, which have shown favorable safety profiles in studies. The company is advancing transformational drug delivery technologies aimed at improving efficacy and safety.
- Positive clinical data reported for SPMS treatment after six months.
- Availability of KOL event replay enhances investor engagement.
- Innovative drug delivery technologies could lead to broad pipeline applications.
- None.
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announces the availability of the replay of its March 14 KOL event entitled “Foralumab Clinical Update in Multiple Sclerosis” along with the slides from the presentation in the Investor Presentations section of its website (https://ir.tizianalifesciences.com/presentation). This morning, Zacks also published a research note to follow up on the KOL presentations and discussion on the positive clinical data after six months of treatment to a SPMS patient.
A replay of the March 14 KOL event is available here
To read the report, please click: https://bit.ly/36eZwBX
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
| Tiziana Life Sciences Ltd Hana Malik, Business Development, and Investor Relations Manager +44 (0) 207 495 2379 email: info@tizianalifesciences.com | |
| Investors: Irina Koffler LifeSci Advisors, LLC 646.970.4681 ikoffler@lifesciadvisors.com |
FAQ
What is the focus of Tiziana Life Sciences?
What was discussed during the Tiziana KOL event on March 14?
Where can I find the slides from Tiziana's March 14 presentation?
What is foralumab and why is it significant?
What kind of research note did Zacks publish regarding TLSA?
